The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.
about
Modelling and simulation as research tools in paediatric drug developmentPersistent pharmacokinetic challenges to pediatric drug developmentStrategic biomarkers for drug development in treating rare diseases and diseases in neonates and infantsA report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage formsHow Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach.Tips and traps analyzing pediatric PK data.Characterizing variability in warfarin dose requirements in children using modelling and simulation.Paediatric models in motion: requirements for model-based decision support at the bedside.Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomicsExpression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric LiverPartnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume.Drug Development for Pediatric Populations: Regulatory Aspects.Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician.The role of physiologically based pharmacokinetic modeling in regulatory review.Physiologically based pharmacokinetic (PBPK) modeling in children.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Methods for pharmacokinetic analysis in young children.Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development.Drug Development of Therapeutic Monoclonal Antibodies.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach.Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.Pharmacokinetic studies in children: recommendations for practice and research.
P2860
Q27010366-18F43F77-3C71-45D2-BD96-22FCA0CBDABBQ27023912-BB684102-8C97-4E87-AA11-BBAEF7F24967Q27024346-8E32FEA5-F7AA-4BF6-AD79-DB515C82FC89Q27027075-A37840F2-0487-4419-BE19-912085A2EB84Q31043972-45725AFA-C479-4F60-9E86-4E90BD0BF351Q33820152-732D5EAF-EABE-425C-A491-190B51ECADB2Q34209582-0DCFA95F-EA88-481B-8C54-9E0CBA932BE0Q34953686-F804C293-F3B6-4AEA-8335-4520D8DC014AQ35800807-B90EC72F-7A84-4934-9A4C-7838874CCB51Q37062634-231E9A39-0FA3-4791-91A1-38BA8C206B2CQ37339294-2E5A3216-95B8-4DCC-AF42-85E9328ACC4DQ37600374-BDA9E376-9FD5-4F4A-A079-CB8BAA3EA9ADQ37666706-F70CD45D-BBC6-4273-846B-447D4A96ADFFQ37692028-07AC51C3-BDB8-4810-B714-E32668CC896AQ37982653-A6102A87-712D-40C1-8828-97717EF2035CQ38016332-69B33BA5-B5D8-4847-84E7-B13B44B4DF99Q38110433-0365E0FC-3446-4B0A-B77C-D4D91FFCE24CQ38187157-753E1D30-9F6B-4923-93A3-6B5B21DA01B8Q38527434-3D4D2E77-8189-478A-8C6B-F97E400812C1Q38853020-EE5FC304-31C1-403A-A959-85DAB5139D6FQ38876360-6D45E0B9-CA4F-4F2F-8E7C-E4EED82CEE34Q39064765-C7DB4A6B-B87A-4586-B0FF-CC3B67E6226CQ39870288-D9411B3D-687C-483C-B904-4D0E9C52E3E3Q41901707-AF9A4870-7E27-4144-A96D-EC5B9ABC491BQ41975490-0FD02EF8-83BF-44FA-B8E5-20D982B8C90BQ42582591-65F87D38-0F16-406A-B7DF-FFB9642B50B6Q51796989-5C7D8203-CB8E-4CA8-AD5F-55029A27BF8DQ52576551-33A6A4B9-2251-4C75-8B53-0018A2D64DF3
P2860
The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The in silico child: using sim ...... age pediatric pharmacotherapy.
@en
The in silico child: using sim ...... age pediatric pharmacotherapy.
@nl
type
label
The in silico child: using sim ...... age pediatric pharmacotherapy.
@en
The in silico child: using sim ...... age pediatric pharmacotherapy.
@nl
prefLabel
The in silico child: using sim ...... age pediatric pharmacotherapy.
@en
The in silico child: using sim ...... age pediatric pharmacotherapy.
@nl
P2860
P356
P1476
The in silico child: using sim ...... nage pediatric pharmacotherapy
@en
P2093
Jeffrey S Barrett
Stephanie Läer
P2860
P304
P356
10.1177/0091270009337513
P577
2009-06-16T00:00:00Z